Skip to content

Study · Randomized controlled trial · n = 456 · 2010

2 results

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.

Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K, Trautmann M

Lancet (London, England)1 Jun 2010Cited by 337 (Europe PMC)

PMID20609969 (opens in a new tab)DOI10.1016/s0140-6736(10)60406-0 (opens in a new tab)PepBankPUB-20609969
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, exenatide reduced HbA1c more than insulin glargine at 26 weeks.

    In plain wordsIn patients with diabetes, exenatide reduced HbA1c more than insulin glargine at 26 weeks.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHbA1c change
    Study

    n = 448

    Comparator
    Insulin glargine
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2 mg once weekly · injection · 26 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −1.5%
    exenatide
    HbA1c change
    −1.3%
    insulin glargine
    Treatment difference
    −0.16%
    exenatide versus insulin glargine

    Source sentences

    Summary
    Change in HbA(1c) at 26 weeks was greater in patients taking exenatide (n=228; -1.5%, SE 0.05) than in those taking insulin glargine (n=220; -1.3%, 0.06; treatment difference -0.16%, 0.07, 95% CI -0.29 to -0.03).
    3 context sentences
    Summary · context
    The primary endpoint was change in HbA(1c) from baseline, and analysis of this outcome was by modified intention to treat for all patients who received at least one dose of study drug.
    Summary · context
    In this 26-week, open-label, randomised, parallel study, we compared exenatide with insulin glargine in adults with type 2 diabetes who had suboptimum glycaemic control despite use of maximum tolerated doses of blood-glucose-lowering drugs for 3 months or longer.
    Summary · context
    Patients were randomly assigned to add exenatide (2 mg, once-a-week injection) or insulin glargine (once-daily injection, starting dose 10 IU, target glucose range 4.0-5.5 mmol/L) to their blood-glucose-lowering regimens.
  2. 02HumanRandomized controlled trialSafety outcome

    In patients with type 2 diabetes, discontinuations due to adverse events were more frequent with exenatide than insulin glargine.

    In plain wordsIn patients with diabetes, more patients discontinued exenatide than insulin glargine because of side effects.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseDiscontinuation due to adverse events
    Study

    n = 456

    Comparator
    Insulin glargine
    Outcome group
    Adverse events · Whole body
    Studied dose
    2 mg once weekly · injection · 26 weeksAs given in this study (human).

    Measurements

    Adverse event discontinuation
    5%
    exenatide
    Adverse event discontinuation
    1%
    insulin glargine
    Adverse event discontinuation
    12 patients
    exenatide
    Adverse event discontinuation
    2 patients
    insulin glargine

    Source sentences

    Summary
    12 (5%) of 233 patients allocated to exenatide and two (1%) of 223 taking insulin glargine discontinued participation because of adverse events (p=0.012).
    2 context sentences
    Summary · context
    In this 26-week, open-label, randomised, parallel study, we compared exenatide with insulin glargine in adults with type 2 diabetes who had suboptimum glycaemic control despite use of maximum tolerated doses of blood-glucose-lowering drugs for 3 months or longer.
    Summary · context
    Patients were randomly assigned to add exenatide (2 mg, once-a-week injection) or insulin glargine (once-daily injection, starting dose 10 IU, target glucose range 4.0-5.5 mmol/L) to their blood-glucose-lowering regimens.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials3

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

3 trials · 2 completed · 1 stopped early · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

TerminatedPhase 3NCT03419624

The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients

Universitätsklinikum Hamburg-Eppendorfn = 1319 Feb 2018 to 5 Aug 2019

Obesity · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 31 Mar 2020
CompletedPhase 4NCT02380521

Exenatide Once Weekly, Cardiovascular Risk and Type-2 Diabetes

University of Palermon = 60Jan 2015 to Nov 2016

Type 2 Diabetes Mellitus

Trial pageClinicalTrials.govUpdated 8 Nov 2016
CompletedPhase 3Results postedNCT00641056

Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)

AstraZenecan = 467Apr 2008 to Nov 2009

Type 2 Diabetes Mellitus

Trial pageClinicalTrials.govUpdated 15 Jun 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.